Neuromyelitis optica in a pediatric patient

Main Article Content

Rafael Mauricio Cabrera Ávial
Manuel José González Delgado
María Antonia Perdomo García
María Alejandra Hanrryr Murillo
María de los Ángeles Vargas Sánchez

Abstract

Background:  neuromyelitis optica is mainly characterized by severely affecting the spinal cord and optic nerves, either in a single clinical episode or in outbreaks and remissions, being a cause of disability in young people and adults. It is classified as an optic-medullary variant of multiple sclerosis. However, studies suggest differences between the two, mainly due to the presence of a specific antibody in the blood called Immunoglobulin G anti-neuromyelitis optica (IgG-NMO) or anti-aquaporin 4 (AQP4) that binds to water channels scattered in the central nervous system (CNS). AQP4 is also offered as a diagnostic test. Case report: this is a pediatric patient diagnosed with neuromyelitis optica, with visual symptoms and motor involvement in the lower extremities, treated with oral azathioprine and later rituximab, with an adequate response to management. Conclusion: NMO should be considered in the pediatric age, the differential diagnosis of multiple sclerosis, and early management should be started to avoid complications and recurrences.

Downloads

Download data is not yet available.

Article Details

How to Cite
Cabrera Ávial, R. M., González Delgado, M. J., Perdomo García, M. A., Hanrryr Murillo, M. A., & Vargas Sánchez, M. de los Ángeles. (2022). Neuromyelitis optica in a pediatric patient. Pediatría, 54(4), 167–170. https://doi.org/10.14295/rp.v54i4.170
Section
Case report

References

Claudio Meza P. , Alejandro Henríquez C. , Andrés Jara Q. y Pilar Canales F; Clinical aspects in neuromyelitis optica spectrum disorders: literature review; REV CHIL NEURO-PSIQUIAT 2016; 54 (3): 228-238.

Beekman J, Yeaman M, et al; Neuromyelitis optica spectrum disorder; Neurol Neuroimmunol Neuroinflamm 2019;6:e580. DOI: https://doi.org/10.1212/NXI.0000000000000580

Wingerchuk D, Lennon V, Pittock s, et al; Revised diagnostic criteria for neuromyelitis optica Neurology May 2006, 66 (10) 1485-1489. DOI: https://doi.org/10.1212/01.wnl.0000216139.44259.74

Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364: 2106-12. DOI: https://doi.org/10.1016/S0140-6736(04)17551-X

Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol 2007; 6: 805- 15. DOI: https://doi.org/10.1016/S1474-4422(07)70216-8

Mandler RN. Neuromyelitis optica - Devic’s syndrome, update. Autoimmun Rev. 2006. DOI: https://doi.org/10.1016/j.autrev.2006.02.008

Meza C; Henríquez A; Jara A; Canales P. Aspectos clínicos en el espectro de neuromielitis óptica: revisión de la literatura Clinical aspects in neuromyelitis optica spectrum disorders: literature review. Artículo de revisión; Chile; 08 - 2016. DOI: https://doi.org/10.4067/S0717-92272016000300007

Pittock SJ. Neuromyelitis optica: a new perspective. Seminars in Neurol 2008. DOI: https://doi.org/10.1055/s-2007-1019131

Quintero P, Gutierrez AM; Neuromielitis óptica, reporte de caso. Revistas científicas de salud. Bogotá, Colombia. Abril 2009.

Similar Articles

<< < 15 16 17 18 19 20 21 22 23 > >> 

You may also start an advanced similarity search for this article.